Back to Awarded Treatment Trials
Awarded Trial: 98-STN-001
Ethyl Eicosapentanoic Acid
Secondary Drug Intervention
Duration of Study Period for Each Subject
MADRAS, RBANS, AIMS, PANSS
A double-blind, randomly assigned placebo-controlled 16 week trial of omega-3 fatty acid augmentation of antipsychotic treatment in 87 schizophrenic and schizoaffective patients who had residual symptoms was conducted. Improvement in residual symptoms and cognitive impairment for patients treated with 3g/day of ethyl EPA was similar to that seen with placebo.
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. Placebo-controlled trial of omega-3 fatty acid (EPA) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001 Dec;158(12):2071-4.
Division of Mental Disorders, Behavioral Research and Aids
NIH, National Institute of Mental Health
6001 Executive Boulevard, Room 6217, MSC 9621
City or Town
State or Province
Zip or Postal Code